Why Primary Care Could Be the Real Longevity Breakthrough

The future of medicine isn’t locked in elite labs or billion-dollar research centers — it’s sitting in the very place most of us overlook: primary care. I…

Published August 23, 202537:16The Longevity Show

Less than 3% of US healthcare dollars go to preventive care. That number explains most of what people find frustrating about their annual physical, and it is the number Dr. Lin builds this episode around — an argument that the longevity breakthrough people are waiting for is not a molecule or a clinic in Switzerland, but a functioning primary care system. She is direct about the personal stake: the reactive, volume-driven model burned her out, and burned out most of the colleagues she trained with.

The diagnosis is that primary care was designed to be the quarterback of a person's health and has been reduced to triage. The annual physical now covers the loosest screening protocols to confirm you are not at critical risk of dying in the next year or two, and anything without a 10% chance of killing you this decade gets punted. Kicking that can down the road is not neutral — it lets the underlying disease develop unobserved.

The rest of the episode is the build. What a health-span-focused assessment actually contains, from hsCRP and fasting insulin to lipoprotein(a) and APOE status. Where AI genuinely changes the economics rather than just the marketing — including her contrarian read that it will reduce the need for specialists rather than generalists. A survey of the payment models now emerging, concierge through telemedicine through gyms and med spas, with the business logic and the failure mode of each. And a closing set of specific actions for clinicians, builders, investors and patients.

Before you watch

The incentive problem comes before the clinical problem, and it explains the room you are sitting in. Fee-for-service pays for volume, so clinics are built to turn patients over — Dr. Lin notes she has worked in clinics without windows, because experience and design lose to throughput every time. The downstream consequence is the statistic she keeps returning to: under 3% of US healthcare spending goes toward prevention. Nothing about the clinical model changes until the payment model does.
A health-span-focused assessment is a different panel, not a longer version of the same one. Beyond CBC, CMP and a basic lipid panel, she looks for inflammatory markers like hsCRP — associated with elevated risk of cardiovascular disease, neurodegenerative disease and certain cancers — full thyroid and sex hormone profiles rather than a lone TSH, and a metabolic panel including fasting insulin and HbA1c to read insulin sensitivity rather than just glucose. Lipoprotein(a) is her example of a test many physicians have still never ordered despite what it adds to cardiovascular risk.
Genomics earns its place when it changes behaviour rather than just satisfying curiosity. Her example is APOE4, where knowing you carry the variant associated with elevated Alzheimer's risk can motivate lifestyle changes and targeted intervention while there is still time for them to matter. The same logic runs through her personalization examples — most people absorb relatively little cholesterol from their diet, but she cites roughly a third of the population as hyperabsorbers taking up over 60%, a group for whom dietary advice should differ from the standard script.
Supplementation in this model is specified rather than recommended. Her illustration is vitamin D: the finding of a low level is the easy part, and the useful part is the right formulation, the right dose, and the cofactors — vitamin K and magnesium — that vitamin D needs to be activated and metabolized. The general principle is that generic advice is the failure mode she is trying to eliminate, whether the subject is supplements, exercise or diet.
The clinician's role shifts from gatekeeper to something closer to a longevity specialist and partner, and Dr. Lin makes the case that this is better for the doctor too. Every visit becomes an opportunity to act on the slightest negative movement in a biomarker rather than to ask whether anything is wrong today. Her own disclosure is unambiguous: she is significantly happier practicing this way than in the revolving-door model, and she frames clinician burnout as a systems risk rather than a personal one.
The public is not sold on AI in health, and Dr. Lin treats that scepticism as legitimate rather than as an obstacle to route around. A 2024 KFF poll found 63% of the public are not confident that AI chatbots provide accurate health information — reasonable, she notes, given how often hallucinations occur. Meanwhile 17% of adults already use them for health information, which she expects to grow the way Dr. Google did. Her position is that the clinician's job is to be the translator between raw AI output and a real person, and that even doctors can be fooled by a confident hallucination.
Her most contrarian claim is about who AI displaces. The consensus fear is that AI replaces generalists; her argument is the opposite — AI will be a better specialist than any human can be, so the future needs more generalists who can wield it and fewer clinicians who understand one organ deeply. She acknowledges the obstacle honestly: billing codes currently make specialization the only route to real income in US medicine. She addresses the point directly to medical students.
Where AI actually changes the economics is less glamorous than diagnosis. She cites imaging analysis and pattern detection across history, genomics, biomarkers and lifestyle — including companies reading early cardiovascular disease off retinal images — plus remote monitoring that can catch a gait change signalling fall risk, or sleep apnea and atrial fibrillation from an Apple Watch. But the biggest lever is administrative: scheduling, claims, records and billing absorbed by software, returning time to patient contact. Her implementation advice is to adopt AI-first platforms outright rather than bolting AI onto legacy software, which she considers harder and more expensive.
Concierge medicine solves the time problem and creates an access problem. Panels drop from thousands of patients to one or two hundred, appointments lengthen, and direct-pay membership outside insurance frees the practice to be genuinely preventive — which is why these practices tend to be early adopters. The cost is the catch: she puts the floor around $1,000 a year and says she has seen figures ranging up to the millions, which makes concierge a proof of concept for the clinical model rather than a distribution strategy for it.
Telemedicine is the scaling mechanism, and Dr. Lin names its specific business failure mode. She converted her own practice fully to telemedicine, citing lower patient cost, reach into remote areas, easier frequent check-ins and natural integration with remote monitoring — with many insurers now reimbursing visits. But because patients can switch platforms trivially, telemedicine-only businesses have weak defensibility and compete on price, which drags quality down with it. Her point is that this is a business design problem rather than an inherent flaw in the modality.
The hybrid and non-clinical models are where she sees the most interesting movement. Hybrid combines an in-person site for DEXA, VO2 max and blood draws with telemedicine for the consultation itself — which is what most patients actually prefer — though Manhattan real estate makes the physical footprint expensive to scale. Beyond that, luxury gyms like Equinox and Life Time are adding biomarker testing and primary-care-like consultations at membership tiers she has seen run from a few thousand to $50,000 a year, and med spas are moving from Botox into GLP-1s and hormone therapy. Her warning on med spas is specific: many are run by non-clinical leadership with a nurse performing procedures, so check who is actually in charge before you buy.

Chapters

02:05

Longevity in Practice: Steps You Can Take Today

Questions

What tests should a real preventive physical include?

Dr. Lin's list goes well past the standard CBC, CMP and basic cholesterol panel. She wants inflammatory markers, particularly hsCRP, which is associated with increased risk of cardiovascular disease, neurodegenerative disease and certain cancers. She wants full hormonal profiling rather than a single TSH — complete thyroid function plus sex hormones. She wants a metabolic panel that includes fasting insulin and HbA1c, because those read insulin sensitivity rather than just current glucose. And she singles out lipoprotein(a) as a test many physicians have never ordered despite what it adds to cardiovascular risk assessment. Alongside the bloodwork sit genomic risk assessment and a detailed lifestyle and environmental review including diet, sleep, stress and toxin exposure.

Is concierge medicine worth it?

Dr. Lin's assessment is that concierge practices genuinely deliver the clinical model she is advocating, and that the price makes them a poor answer to the broader problem. The mechanism is simple: an annual membership outside insurance lets a physician carry one or two hundred patients instead of thousands, which produces longer appointments, better access and the time required for preventive work. That structure also makes concierge practices natural early adopters of longevity-focused care. But she puts the entry point around $1,000 a year and says she has seen prices climbing into the millions, which is why she treats the model as a demonstration of what is possible rather than a way to make it accessible.

Will AI replace doctors?

Dr. Lin's position is that AI replaces tasks rather than clinicians, and that the tasks it takes first are the ones driving burnout — scheduling, claims processing, records management, billing. On the clinical side she sees it as an assistant that can read imaging quickly, find patterns across genomics and biomarkers and lifestyle data, and flag risk years before symptoms appear. Her more provocative claim is about which doctors are actually exposed: she argues AI will be a better specialist than any human can be, so the future needs more generalists who can use it well and fewer narrow subspecialists. The constraint she identifies is the human one — the clinician has the trusted relationship that lets a patient distinguish signal from noise, and even physicians can be misled by confident hallucinations.

Why is the annual physical so useless?

Because of what it was designed to do. Dr. Lin describes it as covering the loosest screening protocols required to establish that you are not at critical risk of death in the next year or two — anything that does not carry roughly a 10% chance of killing you this decade gets deferred to a future visit. That deferral is not neutral, because the underlying disease continues developing while nobody is watching, which is how a preventable condition becomes a chronic one. The root cause is financial rather than clinical: fee-for-service reimbursement rewards volume, so the visit is built for throughput, and less than 3% of US healthcare spending goes toward prevention. She notes this is the norm internationally, not just in the US.

What should I ask my doctor to do differently?

Dr. Lin's instruction is to stop treating the appointment as a place to report symptoms and start treating it as a place to build a plan. Ask directly about longevity medicine, advanced diagnostics and a personalized health plan, and expect a partner rather than a gatekeeper. If your current physician is not interested, her advice is to find one who is — she points out that people research an air fryer for hours and choose a doctor casually, and argues the priority should be reversed. She also suggests coming in with your own data: wearables tracking activity, sleep and heart rate variability give a clinician something continuous to work from, and if you dislike technology, a step tracker is enough to start.

Are wellness clubs and med spas a good place to get longevity care?

Dr. Lin finds the trend genuinely interesting and is more cautious about one branch of it than the other. Luxury gyms such as Equinox and Life Time already sell supplements, personal training and nutrition counselling, and are now adding biomarker testing and primary-care-like consultations — which she considers a sensible fit, since people already exercising are the most likely to act on health-span interventions. Pricing there runs from a few thousand to around $50,000 a year on membership tiers, with no insurance-covered version she has seen. Med spas are moving in a similar direction, adding GLP-1 weight loss, hormone optimization and IV therapy to a cosmetic base. Her caution is specific to that model: many med spas are run by entirely non-clinical leadership with a nurse performing procedures, so check who is clinically responsible before you become a patient.

The Longevity Letter